newsfilter
← Latest News
GlobeNewswire·

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027

Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review Vouchers